Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants-Reference-Cited by-全球学者库

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants

Published:2022-03-15 Issue:1 Volume:11 Page:829-840
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Zhao Zhuxiang¹,Cui Tingting²³,Huang Mingzhu²³,Liu Shuo⁴,Su Xiaoling²³,Li Guichang²³,Song Tao²³,Li Weidong²³,Zhong Nanshan²³,Xu Miao⁴,Yang Xiaoyun²³,Huang WeiJin⁴,Wang Zhongfang²³

Affiliation:

1. Department of Infectious Disease, Respiratory and Critical Care Medicine, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, People’s Republic of China

2. State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China

3. Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China

4. National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products & NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing, People’s Republic of China

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2048969

Reference23 articles.

1. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

3. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination

4. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

5. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine;Cell Discovery;2024-01-09

2. Development of an RBD-Fc fusion vaccine for COVID-19;Vaccine: X;2024-01

3. Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting;eBioMedicine;2024-01

4. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos);eClinicalMedicine;2024-01

5. Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial;Emerging Microbes & Infections;2023-12-30